The phrase "research grade" is used as if it were a quality tier, somewhere below pharmaceutical and above industrial. It is not a tier. It is a statement about intended use, and everything that follows from it is about what was and was not checked.
Pharmaceutical grade is a system, not a number
A licensed medicine is made under Good Manufacturing Practice. That phrase covers a great deal: a validated process that produces the same material every time, a specification that every batch must meet before release, a qualified person who signs that it does, a stability programme that proves the shelf life, and a regulator who can walk into the factory unannounced.
The specification for a therapeutic peptide, following the ICH Q6B framework, typically covers identity by at least two methods, purity, each individual impurity above a threshold, total content, water, residual solvents, counter-ion, appearance, sterility, bacterial endotoxin and more1. A batch that fails any one of them is not released.
Crucially, the clinical trials were run on material that met that specification. When the literature says retatrutide produced a given result, it means retatrutide manufactured to that standard did.
Research grade is a characterisation
A research reagent is sold for use in a laboratory, in an assay, in a cell culture, in an animal model. It is not intended to enter a human body, and so the tests that exist to make injection safe are not run.
What a research supplier provides instead is a certificate of analysis for the lot: typically identity by mass spectrometry and purity by HPLC, sometimes net peptide content, sometimes water. The certificate reports what was measured. It does not promise that anything not listed is acceptable, because nothing not listed was checked.
Number of parameter categories, illustrative
Based on ICH Q6B specification categories and typical peptide CoA content. Chart by TrueLab Care.
Sterility is the clearest case. A pharmaceutical injectable is tested to confirm the absence of viable microorganisms and of endotoxin, the bacterial cell-wall fragments that cause fever. A research reagent is not, because in a cell-culture assay or a receptor-binding experiment those parameters either do not matter or are controlled downstream. The reagent is not less pure; it is simply not characterised for a purpose it was not sold for.
Why this matters more for incretin peptides than for most
Three features of the GLP-1 class make the distinction sharper than usual.
They are large, modified peptides with a fatty-acid chain, and the synthesis is difficult. The space of possible impurities, truncated sequences, incompletely acylated species, oxidised residues, is wider than for a short unmodified peptide.
They are dosed weekly with a half-life of days, so any impurity that is present persists.
And they have unusually high commercial demand, which is the condition under which analytical studies have found online products with content far from label. A 2024 study that test-purchased semaglutide from online sellers found that the active content exceeded the label by 29 to 39 per cent while measured purity was between 7.7 and 14.4 per cent, against advertised figures near 9923. Those were products sold for human use without a prescription, not research reagents, but the analytical finding is the point: a label is a claim until a chromatogram supports it.
Reading a certificate correctly
The useful questions are not "what is the purity?" but these:
Was identity confirmed by mass spectrometry, and does the observed mass match the theoretical mass for the full modified peptide including the fatty-acid chain? A mass match for the bare sequence without the chain is a different molecule.
Is the HPLC chromatogram shown, or only a number? A number without a trace cannot be checked.
Is the net peptide content stated separately from purity? Purity is the fraction of the peptide-related material that is the right peptide; content is how much of the vial's mass is peptide at all. A vial of 99 per cent pure peptide at 70 per cent content contains 30 per cent water and counter-ion.
What is not on the certificate? Sterility and endotoxin almost never are. That absence is normal for a reagent and is the reason a reagent is not a medicine.
The honest summary
The trial literature for retatrutide, tirzepatide and the rest describes molecules made to a pharmaceutical specification, tested on every batch, and administered under protocol. A research reagent bearing the same name is characterised to a narrower standard for a different purpose. The sequence may be identical. The evidence that it is identical rests entirely on the certificate, and the certificate only ever says what was measured.